California State Teachers Retirement System lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 1.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,208 shares of the biopharmaceutical company’s stock after purchasing an additional 573 shares during the quarter. California State Teachers Retirement System owned about 0.07% of Xenon Pharmaceuticals worth $1,475,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the business. BNP Paribas Arbitrage SA increased its stake in shares of Xenon Pharmaceuticals by 1,567.5% during the first quarter. BNP Paribas Arbitrage SA now owns 1,334 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 1,254 shares during the period. Wells Fargo & Company MN increased its stake in Xenon Pharmaceuticals by 124.6% in the fourth quarter. Wells Fargo & Company MN now owns 1,123 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 623 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Xenon Pharmaceuticals in the first quarter valued at approximately $66,000. UBS Group AG boosted its holdings in shares of Xenon Pharmaceuticals by 102.1% in the second quarter. UBS Group AG now owns 2,472 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 1,249 shares during the period. Finally, Deutsche Bank AG acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $98,000. Institutional investors and hedge funds own 95.70% of the company’s stock.
Xenon Pharmaceuticals Trading Up 0.8 %
NASDAQ XENE opened at $38.88 on Thursday. The business’s 50-day moving average price is $37.95 and its 200 day moving average price is $38.29. Xenon Pharmaceuticals Inc. has a twelve month low of $31.79 and a twelve month high of $43.75. The company has a market capitalization of $2.49 billion, a PE ratio of -15.61 and a beta of 1.39.
Insider Transactions at Xenon Pharmaceuticals
In other news, Director Dawn Svoronos sold 25,000 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $38.70, for a total value of $967,500.00. Following the transaction, the director now directly owns 25,000 shares in the company, valued at approximately $967,500. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 5.43% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on XENE. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, August 10th. Stifel Nicolaus increased their price target on Xenon Pharmaceuticals from $52.00 to $53.00 in a report on Wednesday, May 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $58.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, August 22nd. Wedbush reissued an “outperform” rating and issued a $47.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, August 10th. Finally, StockNews.com assumed coverage on Xenon Pharmaceuticals in a report on Thursday, August 17th. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.40.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
- Five stocks we like better than Xenon Pharmaceuticals
- What Are Dividends? Buy the Best Dividend Stocks
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- Do ETFs Pay Dividends? What You Need to Know
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- How to Invest in Biotech Stocks
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.